US2015315237A1PendingUtilityA1

NMDA Receptor Modulators and Uses Thereof

Assignee: UNIV NORTHWESTERNPriority: Feb 11, 2010Filed: Jan 23, 2014Published: Nov 5, 2015
Est. expiryFeb 11, 2030(~3.5 yrs left)· nominal 20-yr term from priority
A61P 43/00A61P 25/18A61P 25/28A61P 25/14A61P 25/22A61P 25/24A61P 25/00C07K 5/0823C07K 5/06165A61K 38/07A61K 38/16A61K 31/397A61K 38/17A61K 38/00A61K 31/48C07D 403/06C07K 5/1013
64
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of diseases and disorders, such as learning, cognitive activities, and analgesia, particularly in alleviating and/or reducing neuropathic pain. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.

Claims

exact text as granted — not AI-modified
What is claimed is:  
     
         1 . A compound represented by: 
       
         
           
           
               
               
           
         
         wherein:
 R 1 , R 2 , R 3 , and R 4  are each independently selected from the group consisting of hydrogen; halogen, C 1 -C 6 alkyl, or —OH; 
 R 5  is hydrogen; 
 
         X is selected from the group consisting of OR x  and NR x R x , wherein R X  is independently selected, for each occurrence, from the group consisting of hydrogen, and C 1 -C 6 alkyl; 
         pharmaceutically acceptable salts, stereoisomers, and hydrates thereof; provided that the compound is not GLYX-13. 
       
     
     
         2 . (canceled) 
     
     
         3 . (canceled) 
     
     
         4 . (canceled) 
     
     
         5 . The compound of  claim 1  represented by: 
       
         
           
           
               
               
           
         
       
     
     
         6 . The compound of  claim 1  represented by: 
       
         
           
           
               
               
           
         
       
     
     
         7 . The compound of  claim 1  represented by: 
       
         
           
           
               
               
           
         
       
     
     
         8 . (canceled) 
     
     
         9 . A pharmaceutical composition, comprising:
 a therapeutically effective amount of a compound of  claim 1  and a pharmaceutically acceptable carrier.   
     
     
         10 . The pharmaceutical composition of  claim 9 , suitable for oral administration. 
     
     
         11 . The pharmaceutical composition of  claim 9 , suitable for injection. 
     
     
         12 . A method of treating depression, Alzheimer's disease, attention deficit disorder, ADHD, schizophrenia, or anxiety, in a patient in need thereof, comprising administering to said patient:
 a pharmaceutically effective amount of a compound of  claim 1 .

Join the waitlist — get patent alerts

Track US2015315237A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.